A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
Related Stories
UCB acquires Candid for $2B to pursue T‑cell engager therapies / 3 months
Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 5 months
AstraZeneca explores $400B merger talks with Bristol Myers Squibb / 21 days
Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 4 months
Merck to acquire Terns Therapeutics for $6.7B / 5 months
Servier to acquire Day One Biopharma for $2.5B / 5 months
Dendritic cells build tumour immune hubs sustaining anti-tumour responses / 6 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Nutrition, Olfaction, Infectious Disease, Hearing Loss and look for the RSS link.
StackHealth Time Machine